avapro has been researched along with Insulin Resistance in 21 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recent studies from our laboratory indicate that chlorthalidone triggers persistent activation of the sympathetic nervous system and promotes insulin resistance in hypertensive patients, independent of serum potassium." | 9.16 | Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. ( Adams-Huet, B; Arbique, D; Auchus, RJ; Price, A; Raheja, P; Vongpatanasin, W; Wang, Z, 2012) |
| "Essential hypertension is frequently associated with insulin resistance of skeletal muscle glucose transport, and angiotensin II (ANGII) can contribute to the pathogenesis of both conditions." | 7.73 | Selective angiotensin II receptor antagonism enhances whole-body insulin sensitivity and muscle glucose transport in hypertensive TG(mREN2)27 rats. ( Diehl, CJ; Henriksen, EJ; Kim, JS; Saengsirisuwan, V; Sloniger, JA, 2005) |
| "Of the pleiotropic effect related parameters investigated, urinary 8-isoprostane, fasting serum insulin and homeostasis model assessment of insulin resistance index were more suppressed after 4 weeks treatment with irbesartan than after candesartan and valsartan therapy, respectively." | 5.17 | Relationship between the receptor occupancy profile and pleiotropic effects of angiotensin II receptor blockers. ( Ando, H; Fujimura, A; Hosohata, K; Saito, T; Ushijima, K, 2013) |
| "Recent studies from our laboratory indicate that chlorthalidone triggers persistent activation of the sympathetic nervous system and promotes insulin resistance in hypertensive patients, independent of serum potassium." | 5.16 | Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. ( Adams-Huet, B; Arbique, D; Auchus, RJ; Price, A; Raheja, P; Vongpatanasin, W; Wang, Z, 2012) |
| "We examined the effects of ARB administration on hyperinsulinemia-associated capillary density by measuring baseline skin capillary density, capillary density during reactive hyperemia (hyperemic capillary recruitment), and capillary density during venous congestion in 17 hypertensive individuals in the basal state, during a hyperinsulinemic euglycemic clamp, and during a hyperinsulinemic clamp with acute ARB administration (600 mg irbesartan), acute calcium channel blockade (CCB; 10mg felodipine ER), as a control for the reduction in blood pressure, or placebo." | 5.15 | Acute angiotensin II receptor blockade improves insulin-induced microvascular function in hypertensive individuals. ( de Leeuw, PW; Houben, AJ; Jonk, AM; Schaper, NC; Serné, EH; Smulders, YM; Stehouwer, CD, 2011) |
| " In this study, thirteen-week-old spontaneously hypertensive (SHR)/NDmcr-cp rats, representing a genetic model of metabolic syndrome, were treated daily with placebo, irbesartan (30 mg/kg), valsartan (10 mg/kg), or pioglitazone (10 mg/kg) for 4 weeks." | 3.77 | Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ. ( Jin, D; Miyazaki, M; Takai, S, 2011) |
| "Essential hypertension is frequently associated with insulin resistance of skeletal muscle glucose transport, and angiotensin II (ANGII) can contribute to the pathogenesis of both conditions." | 3.73 | Selective angiotensin II receptor antagonism enhances whole-body insulin sensitivity and muscle glucose transport in hypertensive TG(mREN2)27 rats. ( Diehl, CJ; Henriksen, EJ; Kim, JS; Saengsirisuwan, V; Sloniger, JA, 2005) |
| "Angiotensin II (AII) has been shown to contribute to the pathogenesis of hypertension and insulin resistance." | 3.73 | Irbesartan restores the in-vivo insulin signaling pathway leading to Akt activation in obese Zucker rats. ( Argentino, DP; Dominici, FP; Muñoz, MC; Toblli, JE; Turyn, D, 2006) |
| "Impaired insulin sensitivity is common in patients with chronic systolic heart failure (CHF) and contributes to symptomatic status and impaired prognosis." | 2.77 | Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo-controlled study. ( Anker, SD; Doehner, W; Kennecke, C; Lainscak, M; Rauchhaus, M; Sandek, A; Todorovic, J; Tschöpe, C; van Linthout, S; von Haehling, S, 2012) |
| "The potential benefit for treatment of the metabolic syndrome, cardiovascular protection, and prevention of related end-organ complications could be of immense clinical value." | 2.43 | Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. ( Pershadsingh, HA, 2006) |
| "Telmisartan is an angiotensin Type 1 (AT(1))-receptor antagonist being used in the treatment of hypertension." | 2.42 | Telmisartan - killing two birds with one stone. ( Doggrell, SA, 2004) |
| " After chronic administration of irbesartan (21 days at 50 mg." | 1.31 | Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. ( Henriksen, EJ; Jacob, S; Kinnick, TR; Krekler, M; Teachey, MK, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (61.90) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, M | 1 |
| Takeshita, K | 1 |
| Uchida, Y | 1 |
| Yamamoto, K | 1 |
| Kikuchi, R | 1 |
| Nakayama, T | 1 |
| Nomura, E | 1 |
| Cheng, XW | 1 |
| Matsushita, T | 1 |
| Nakamura, S | 1 |
| Murohara, T | 1 |
| Russell, JC | 1 |
| Kelly, SE | 1 |
| Vine, DF | 1 |
| Proctor, SD | 1 |
| Muñoz, MC | 2 |
| Giani, JF | 1 |
| Dominici, FP | 2 |
| Turyn, D | 2 |
| Toblli, JE | 2 |
| Parhofer, KG | 1 |
| Birkeland, KI | 1 |
| DeFronzo, R | 1 |
| Del Prato, S | 1 |
| Bhaumik, A | 1 |
| Ptaszynska, A | 1 |
| Kobayashi, T | 1 |
| Akiyama, Y | 1 |
| Akiyama, N | 1 |
| Katoh, H | 1 |
| Yamamoto, S | 1 |
| Funatsuki, K | 1 |
| Yanagimoto, T | 1 |
| Notoya, M | 1 |
| Asakura, K | 1 |
| Shinosaki, T | 1 |
| Hanasaki, K | 1 |
| Jonk, AM | 1 |
| Houben, AJ | 1 |
| Schaper, NC | 1 |
| de Leeuw, PW | 1 |
| Serné, EH | 1 |
| Smulders, YM | 1 |
| Stehouwer, CD | 1 |
| Takai, S | 1 |
| Jin, D | 1 |
| Miyazaki, M | 1 |
| Doehner, W | 1 |
| Todorovic, J | 1 |
| Kennecke, C | 1 |
| Rauchhaus, M | 1 |
| Sandek, A | 1 |
| Lainscak, M | 1 |
| van Linthout, S | 1 |
| Tschöpe, C | 1 |
| von Haehling, S | 1 |
| Anker, SD | 1 |
| Ando, H | 2 |
| Ushijima, K | 1 |
| Hosohata, K | 1 |
| Saito, T | 1 |
| Fujimura, A | 2 |
| Raheja, P | 1 |
| Price, A | 1 |
| Wang, Z | 1 |
| Arbique, D | 1 |
| Adams-Huet, B | 1 |
| Auchus, RJ | 1 |
| Vongpatanasin, W | 1 |
| Schupp, M | 2 |
| Janke, J | 1 |
| Clasen, R | 2 |
| Unger, T | 2 |
| Kintscher, U | 2 |
| Doggrell, SA | 1 |
| Foryst-Ludwig, A | 1 |
| Sprang, C | 1 |
| Clemenz, M | 1 |
| Krikov, M | 1 |
| Thöne-Reineke, C | 1 |
| Pershadsingh, HA | 1 |
| Sloniger, JA | 1 |
| Saengsirisuwan, V | 1 |
| Diehl, CJ | 1 |
| Kim, JS | 1 |
| Henriksen, EJ | 2 |
| Argentino, DP | 1 |
| Rakugi, H | 1 |
| Ogiwara, T | 1 |
| Derosa, G | 1 |
| Cicero, AF | 1 |
| D'Angelo, A | 1 |
| Ragonesi, PD | 1 |
| Ciccarelli, L | 1 |
| Piccinni, MN | 1 |
| Pricolo, F | 1 |
| Salvadeo, SA | 1 |
| Ferrari, I | 1 |
| Gravina, A | 1 |
| Fogari, R | 1 |
| Mayer, MA | 1 |
| Höcht, C | 1 |
| Gironacci, M | 1 |
| Opezzo, JA | 1 |
| Taira, CA | 1 |
| Fernández, BE | 1 |
| Puyó, AM | 1 |
| Jacob, S | 1 |
| Kinnick, TR | 1 |
| Teachey, MK | 1 |
| Krekler, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome[NCT00110422] | Phase 4 | 400 participants | Interventional | 2005-11-30 | Completed | ||
| Effect of the Angiotensin II Receptor Antagonist Irbesartan on Insulin Sensitivity and Metabolic Profile in Patients With Chronic Heart Failure[NCT00347087] | Phase 4 | 36 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Neural Mechanisms of Thiazide-induced Insulin Resistance[NCT00353652] | Phase 4 | 166 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Exploring the Health Benefits Associated With Daily Pulse Consumption in Individuals With Peripheral Arterial Disease[NCT00755677] | Early Phase 1 | 26 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00353652)
Timeframe: Measured at 3 months
| Intervention | mmHg (Mean) |
|---|---|
| Study#1: Chlorthalidone (CTD), Titrated Dose | 127.4 |
| Study #1: Spironolactone (SP), Titrated Dose | 128.6 |
| Study# 2 Chlorthalidone (CTD), Fixed Dose | 123.5 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose | 121.6 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose | 119.8 |
assessment of insulin resistance calculated by multiplying fasting plasma insulin (mU/l) with fasting plasma glucose (mmol/l) divided by 22.5. (NCT00353652)
Timeframe: 3 months
| Intervention | mU/l*mmol/l (Median) |
|---|---|
| Study#1: Chlorthalidone (CTD), Titrated Dose | 1.91 |
| Study #1: Spironolactone (SP), Titrated Dose | 1.33 |
| Study# 2 Chlorthalidone (CTD), Fixed Dose | 1.87 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose | 0.85 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose | 1.42 |
fasting plasma insulin (NCT00353652)
Timeframe: 3 months
| Intervention | mU/liter (Median) |
|---|---|
| Study#1: Chlorthalidone (CTD), Titrated Dose | 8.24 |
| Study #1: Spironolactone (SP), Titrated Dose | 7.6 |
| Study# 2 CTD Fixed Dose 25 mg/d | 7.6 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose | 4.87 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose | 6.8 |
slope relating percent change in SNA (% change in total activity from baseline) to diastolic BP. (NCT00353652)
Timeframe: 3 months
| Intervention | % change from baseline per mmHg (Mean) |
|---|---|
| Study#1: Chlorthalidone (CTD), Titrated Dose | -9.1 |
| Drug: Study #1: Spironolactone (SP), Titrated Dose | -15.2 |
| Study# 2 Chlorthalidone (CTD), Fixed Dose | -12.9 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose | -11.3 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose | -12.0 |
(NCT00353652)
Timeframe: Measured at 3 months
| Intervention | bursts/min (Mean) |
|---|---|
| Study#1: Chlorthalidone (CTD), Titrated Dose | 46 |
| Study #1: Spironolactone (SP), Titrated Dose | 40 |
| Study# 2 Chlorthalidone (CTD), Fixed Dose | 49 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose | 42 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose | 52 |
3 reviews available for avapro and Insulin Resistance
| Article | Year |
|---|---|
Telmisartan - killing two birds with one stone.
Topics: 3T3-L1 Cells; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl | 2004 |
Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Tri | 2006 |
[Renin-angiotensin system].
Topics: Adipocytes; Amides; Angiotensin-Converting Enzyme 2; Antihypertensive Agents; Biphenyl Compounds; Fu | 2006 |
6 trials available for avapro and Insulin Resistance
| Article | Year |
|---|---|
Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND).
Topics: Adult; Aged; Analysis of Variance; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, T | 2010 |
Acute angiotensin II receptor blockade improves insulin-induced microvascular function in hypertensive individuals.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Glucose; Blood Pressure; Calcium Channel | 2011 |
Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo-controlled study.
Topics: Aged; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Female; Heart Failu | 2012 |
Relationship between the receptor occupancy profile and pleiotropic effects of angiotensin II receptor blockers.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Area Under Curve; Benzimida | 2013 |
Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients.
Topics: Action Potentials; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chlorthalidone; Cros | 2012 |
Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucos | 2006 |
12 other studies available for avapro and Insulin Resistance
| Article | Year |
|---|---|
Angiotensin II receptor blocker ameliorates stress-induced adipose tissue inflammation and insulin resistance.
Topics: Adipokines; Adipose Tissue, White; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals | 2014 |
Irbesartan-mediated reduction of renal and cardiac damage in insulin resistant JCR : LA-cp rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cardiovascular Diseases; Infla | 2009 |
Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Glucose; Blo | 2009 |
Irbesartan enhances GLUT4 translocation and glucose transport in skeletal muscle cells.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biological Transport; Biphenyl Compounds; Body Wei | 2010 |
Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ.
Topics: Adiponectin; Adipose Tissue; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bip | 2011 |
Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.
Topics: 3T3 Cells; Acrylates; Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; | 2004 |
PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
Topics: 3T3-L1 Cells; Adipocytes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimid | 2005 |
Selective angiotensin II receptor antagonism enhances whole-body insulin sensitivity and muscle glucose transport in hypertensive TG(mREN2)27 rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biological Transport; Biphenyl Com | 2005 |
Irbesartan restores the in-vivo insulin signaling pathway leading to Akt activation in obese Zucker rats.
Topics: Adaptor Proteins, Signal Transducing; Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Re | 2006 |
[PPARgamma-activating properties of angiotensin receptor blockers].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arteriosclerosis; Benzimi | 2006 |
Hypothalamic angiotensinergic-noradrenergic systems interaction in fructose induced hypertension.
Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Fructose; Hypertension; Hypothalamus; Insulin | 2008 |
Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats.
Topics: Angiotensin Receptor Antagonists; Animals; Area Under Curve; Biological Transport; Biphenyl Compound | 2001 |